Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

2010/08/14 by J. Joseph Melenhorst, Ann M. Leen, Catherine M. Bollard +6 · 25 citations
Medicine · Immunology and Microbiology · #Cytomegalovirus and herpesvirus research #T-cell and B-cell Immunology #Immune Cell Function and Interaction

paper · pdf · doi:10.1182/blood-2010-06-289991

Abstract

Adoptive transfer of viral antigen-specific memory T cells can reconstitute antiviral immunity, but in a recent report a majority of virus-specific cytotoxic T-lymphocyte (CTL) lines showed in vitro cross-reactivity against allo-human leukocyte antigen (HLA) molecules as measured by interferon-γ secretion. We therefore reviewed our clinical experience with adoptive transfer of allogeneic hematopoietic stem cell transplantation donor-derived virus-specific CTLs in 153 recipients, including 73 instances where there was an HLA mismatch. There was no de novo acute graft-versus-host disease after infusion, and incidence of graft-versus-host disease reactivation was low and not significantly different in recipients of matched or mismatched CTL. However, we found that virus-specific T cell lines recognized up to 10% of a panel of 44 HLA disparate targets, indicating that virus-specific T cells can have cross-reactivity with HLA-mismatched targets in vitro. These data indicate that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vitro recognition of recipient HLA molecules.

Cited by

• TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition. [europepmc]
• Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. [europepmc]
• The impact of infection and tissue damage in solid-organ transplantation. [europepmc]
• T-cell therapy in the treatment of post-transplant lymphoproliferative disease. [europepmc]
• Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. [europepmc]
• The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. [europepmc]
• Antiviral T-cell therapy. [europepmc]
• Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells. [europepmc]
• Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications. [europepmc]
• Therapeutic T cell engineering. [europepmc]
• Immunotherapy for transplantation-associated viral infections. [europepmc]
• Virus-Specific T Cells for the Immunocompromised Patient. [europepmc]
• Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. [europepmc]
• Posttransplant chimeric antigen receptor therapy. [europepmc]
• Virus-specific T-cell therapies for patients with primary immune deficiency. [europepmc]
• Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. [europepmc]
• The Emerging Landscape of Immune Cell Therapies. [europepmc]
• Engineered off-the-shelf therapeutic T cells resist host immune rejection. [europepmc]
• SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. [europepmc]
• Allogeneic CAR Cell Therapy-More Than a Pipe Dream. [europepmc]
• Immunogenicity of CAR T cells in cancer therapy. [europepmc]
• Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. [europepmc]
• GVHD Pathogenesis, Prevention and Treatment: Lessons From Humanized Mouse Transplant Models. [europepmc]
• CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? [europepmc]
• Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? [europepmc]

Related

• Incidence and clinical relevance of donor-derived recipient-specific anti-HLA antibodies in haploidentical hematopoietic stem cell transplantation: a retrospective study
• Cytomegalovirus Antigenic Mimicry of Human Alloreactive Peptides: A Potential Trigger for Graft versus Host Disease
• Reactivation of Latent Human Cytomegalovirus in CD14+Monocytes Is Differentiation Dependent
• The allogeneic graft‐versus‐cancer effect
• Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment